SNUS worth watching on Monday, may be a $8 stock or $2 stock by the open:
Sonus Pharmaceuticals to Hold Conference Call to Discuss Results from Pivotal Phase 3 Trial of TOCOSOL(R) Paclitaxel
Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced that it will hold a conference call on Monday, September 24, to discuss the results from the pivotal Phase 3 clinical trial of TOCOSOL® Paclitaxel, the Company’s lead oncology product candidate.
The conference call will be webcast live on September 24 at 5:00 A.M. PT/8:00 A.M. ET and can be accessed at www.sonuspharma.com/events.html. The call will be archived at the same link. A telephone replay will be available on September 24 at 7:00 A.M. PT/10:00 A.M. ET for one week at 800-405-2236 or 303-590-3000 for international calls; Pass code: 11098211.
About Sonus Pharmaceuticals
Located near Seattle, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety, tolerability and ease of use. The Company’s lead product candidate, TOCOSOL Paclitaxel, is in a Phase 3 pivotal trial in patients with metastatic breast cancer. Sonus’ second product candidate, TOCOSOL Camptothecin, is in a Phase 1 clinical trial. For additional information on the Company, including past news releases, please visit www.sonuspharma.com.
Sonus Pharmaceuticals, Inc.
Pamela L. Dull, 425-487-9500, Ext. 255
Source: Business Wire (September 21, 2007 - 3:30 PM EST)
News by QuoteMedia
www.quotemedia.com
surf's up......crikey
AI
